Antiviral research and drug development targeting the solute carrier superfamily (SLCs)
10.11665/j.issn.1000-5048.2026012304
- VernacularTitle:靶向溶质载体超家族（SLCs）的抗病毒研究与药物研发
- Author:
Liyun DING
1
;
Dongyu LIU
;
Ting ZHOU
;
Wei PAN
;
Jinlei BIAN
Author Information
1. 中国药科大学药学院, 南京210009
- Publication Type:Journal Article
- Keywords:
solute carrier transporter;
host-directed therapy;
broad-spectrum antiviral;
immunity;
metabolism
- From:
Journal of China Pharmaceutical University
2026;57(4):411-421
- CountryChina
- Language:Chinese
-
Abstract:
The solute carrier superfamily (SLCs), comprising over 450 transporter proteins, plays pivotal roles in nutrient absorption, transmembrane transport regulation, and immunometabolism, and is intimately linked to various diseases. This review systematically summarizes the latest progress of SLCs in the antiviral field, focusing on three classification mechanisms: firstly, SLCs function as critical receptors or cofactors for viral entry, mediating viral attachment to and fusion with host cell membranes; secondly, SLCs modulate host innate immune signaling pathways, thereby positively or negatively regulating antiviral immune responses; and thirdly, SLCs serve as transmembrane transporters for antiviral agents, determining their absorption, distribution, and metabolism, which significantly influence therapeutic efficacy. Furthermore, host-targeted antiviral strategies based on these mechanisms and the chemical structures of relevant bioactive molecules are systematically elucidated. Finally, the potential of targeting SLCs for novel antiviral drug development and the associated druggability challenges are discussed in depth, providing a theoretical basis for the molecular design and development of next-generation antiviral agents.
